Are there specific subtypes of cancer with increased incidence in patients taking upadacitinib compared to those who are not?
Abstract
The evidence suggests a generally increased malignancy risk, particularly non-melanoma skin cancers, in patients on upadacitinib, but specific data on increased incidence of particular cancer subtypes directly attributed to upadacitinib use remain limited.
Fields of Study & Subjects
Rheumatoid Arthritis Research and Therapies
Pharmacovigilance and Adverse Drug Reactions
Immunotoxicology and immune responses
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 20 January 2026